Task X6: Evaluation of a Leishmania Vaccine

任务 X6：利什曼原虫疫苗的评估

• 批准号: 8753193
• 负责人: NORMAN KNETEMAN
• 金额: $ 53.8万
• 依托单位: BATTELLE CENTERS/PUB HLTH RES & EVALUATN
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-17 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8753193
• 关键词: Bioterrorism; Clinical; Communicable Diseases; Contracts; Development; Drug resistance; Emerging Communicable Diseases; Evaluation; Feasibility Studies; Leishmania; Phase; Sampling; Services; Testing; Toxicity Tests; Vaccines; assay development; efficacy testing; evaluation/testing; immunogenicity; novel vaccines; pathogen; product development; safety testing; vaccine development

The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through manufacture of Phase I/II material, including assay development; immunogenicity and efficacy testing; clinical and nonclinical sample testing; and safety and toxicity testing. These services will facilitate the development and introduction of new vaccines and biologics against potential agents of bioterrorism, drug-resistant pathogens, and emerging and re-emerging infectious diseases.

传染病疫苗和其他生物制剂的评估和测试服务 (ETS) 合同提供各种产品开发服务，从早期可行性研究到 I/II 期材料的制造，包括分析开发；免疫原性和功效测试；临床和非临床样品检测；以及安全性和毒性测试。这些服务将促进新疫苗和生物制剂的开发和引进，以应对潜在的生物恐怖主义、耐药病原体以及新出现和重新出现的传染病。